HeartSciences Inc. (NASDAQ:HSCS) Short Interest Update

HeartSciences Inc. (NASDAQ:HSCS) saw a significant increase in short interest during the month of August. As of August 31st, there was short interest totaling 114,152 shares, an increase of 125.2% from the August 15th total of 50,682 shares. Approximately 3.1% of the shares of the company are sold short. Based on an average trading volume of 167,140 shares, the days-to-cover ratio is presently 0.7 days.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on HSCS. Wall Street Zen raised shares of HeartSciences to a “sell” rating in a research report on Saturday. Weiss Ratings reissued a “sell (e+)” rating on shares of HeartSciences in a report on Wednesday, June 24th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $8.00.

HeartSciences Trading Up 0.9%

HSCS traded up $0.03 during trading hours on Monday, hitting $3.42. The company’s stock had a trading volume of 42,756 shares, compared to its average volume of 848,126. The stock has a market cap of $13.33 million, a price-to-earnings ratio of -0.87 and a beta of 1.85. The business’s 50-day moving average price is $2.67 and its 200-day moving average price is $2.38. HeartSciences has a 12 month low of $1.63 and a 12 month high of $4.35.

HeartSciences (NASDAQ:HSCS) last announced its earnings results on Thursday, July 23rd. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.22). On average, analysts forecast that HeartSciences will post -3.04 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in HeartSciences stock. DRW Securities LLC boosted its holdings in shares of HeartSciences Inc. (NASDAQ:HSCS) by 13.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 95,065 shares of the company’s stock after acquiring an additional 11,455 shares during the quarter. DRW Securities LLC owned 2.99% of HeartSciences worth $294,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 17.24% of the company’s stock.

HeartSciences Company Profile

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.